Queeny Tower at Barnes-Jewish Hospital to be demolished ksdk.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksdk.com Daily Mail and Mail on Sunday newspapers.
Date Time
Scientists to explore whether anti-inflammatory drugs control blood sugar
Meals prepared for scientific studies of metabolism and nutrition stand ready for distribution at Washington University School of Medicine in St. Louis. Researchers at the School of Medicine are studying whether drugs to treat inflammatory conditions such as Crohn’s disease also could help control blood sugar levels. (Photo: Matt Miller/School of Medicine)
Inflammation and metabolic disorders are deeply intertwined. For example, people with inflammatory conditions such as Crohn’s disease and psoriasis are at risk of developing metabolic disorders such as insulin resistance and diabetes. However troubling that connection might seem, it also might point to some promising news.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic .
Algernon PharmaceuticalsFebruary 1, 2021 GMT
VANCOUVER, British Columbia, Feb. 01, 2021 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.
December 17, 2020 SHARE Joan Niehoff, MD, receives a vaccine against COVID-19 Dec. 17 on the Medical Campus. Health-care workers and other employees in contact with patients received vaccines from the first shipment to arrive on the Medical Campus. (Photo: Matt Miller/School of Medicine)
As part of a historic effort to end the COVID-19 pandemic, health-care personnel at Washington University School of Medicine in St. Louis and BJC HealthCare have begun receiving the first doses of a vaccine against the SARS-CoV-2 virus. Almost 10,000 doses of the Pfizer vaccine will be administered in the coming weeks to School of Medicine and BJC employees who have direct contact with patients, work in patient-care areas or handle potentially infectious materials, such as nasal swab samples. Such patient-facing personnel have been prioritized by the Centers for Disease Control and Prevention (CDC) and the state of Missouri to receive the vaccine first.
A new form of an Alzheimer’s disease protein in the fluid that surrounds the brain and spinal cord indicates what stage of the disease a person is in, and tracks with tangles of tau protein in the brain, according to a new study.
Tau tangles are thought to be toxic to neurons, and their spread through the brain foretells the death of brain tissue and cognitive decline. Tangles appear as the early, asymptomatic stage of Alzheimer’s develops into the symptomatic stage.
The discovery of so-called microtubule binding region tau (MTBR tau) in the cerebrospinal fluid could lead to a way to diagnose people in the earliest stages of Alzheimer’s disease, before they have symptoms or when their symptoms are still mild and easily misdiagnosed.